Spero Therapeutics reported having approximately $52.9 million in cash as of December 31, 2024, and is under SEC investigation regarding past disclosures, leading to interim leadership changes with Esther Rajavelu appointed as Interim CEO.
AI Assistant
SPERO THERAPEUTICS INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.